ÎäÌïÈðÆÕ¼Ñ£¨°¢¼ÓÌÇø¦Á×¢ÉäÓÃŨÈÜÒº£©»ñÅú½øÈëÖйú

·¢²¼Ê±¼ä£º2020-08-30 06:20:02 À´Ô´£º
ÉϺ£2020Äê8ÔÂ28ÈÕ /ÃÀͨÉç/ -- ÎäÌïÖйú½ñÈÕÐû²¼£¬ÆìÏ´´ÐÂÒ©ÎïÈðÆÕ¼Ñ ® £¨°¢¼ÓÌÇø¦Á×¢ÉäÓÃŨÈÜÒº£©¾­¹ú¼ÒÒ©Æ·¼à¶½¹ÜÀí¾ÖÅú×¼£¬ÓÃÓÚÈ·ÕïΪ ·¨²¼Àײ¡£¨¦Á -°ëÈéÌÇÜÕø A ȱ·¦Ö¢£©»¼Õߵij¤ÆÚÃ¸Ìæ´úÖÎÁÆ ¡£ÈðÆÕ¼Ñ ® £¨°¢¼ÓÌÇø¦Á×¢ÉäÓÃŨÈÜÒº£©ÊÇÖйúĿǰÒý½øµÄΨһµÄÈËÔ´ÐÔÃ¸Ìæ´úÁÆ·¨£¬¿É´øÀ´³¤ÆÚµÄÐÄ¡¢Éö±£»¤²¢ÑÓ»º¼²²¡½ø³Ì [1] £¬¸ÄÉÆ»¼Õß¼°Æä¼ÒÍ¥µÄÉú»îÖÊÁ¿¡£
ÎäÌïÈðÆÕ¼Ñ£¨°¢¼ÓÌÇø¦Á×¢ÉäÓÃŨÈÜÒº£©»ñÅú½øÈëÖйú

ÈðÆÕ¼Ñ®£¨°¢¼ÓÌÇø¦Á×¢ÉäÓÃŨÈÜÒº£©ÓÚ2001ÄêÂÊÏÈÔÚÅ·ÃË»ñµÃÉÏÊÐÐí¿É¡£½ØÖ¹ÖÁ2019Äê4Ô£¬ÒÑÔÚ³¬¹ý63¸ö¹ú¼Ò/µØÇøÉÏÊУ¬ÔÚÈ«Çò·¶Î§ÄÚÀÛ»ýÁ˸ߴï20ÄêµÄÕæÊµÊÀ½çʹÓþ­Ñ飬³¬¹ý31,000Ãû»¼Õß»ñÒæ¡£2018Äê3Ô£¬ÈðÆÕ¼Ñ®£¨°¢¼ÓÌÇø¦Á×¢ÉäÓÃŨÈÜÒº£©åàÑ¡½øÈë¹ú¼ÒÒ©Æ·¼à¹Ü¾ÖÒ©Æ·ÉóÆÀÖÐÐÄ·¢²¼µÄµÚ¶þÅúÁÙ´²¼±Ðè¾³ÍâÐÂÒ©Ãûµ¥[2]£¬Í¨¹ýרÃÅͨµÀµÄ¼ÓËÙÉóÆÀºÍÉóÅú£¬Èøùú¼Ê´´ÐÂÒ©ÎïѸËٻݼ°Öйú»¼Õß¡£

·¨²¼Àײ¡ÊÇÒ»ÖÖº±¼ûµÄXÁ¬ËøÒÅ´«ÐÔÈÜøÌåÖü»ý²¡£¬»¼ÕßÌåÄÚ´úл²úÎïÈý¼ºÌÇõ£»ùÇÊÖ¬´¼£¨GL3£©²»Äܱ»Áѽ⣬ÔÚ¸÷×éÖ¯ºÍÆ÷¹Ù´óÁ¿Öü»ý£¬µ¼Ö»¼ÕßÊÖ½Åͨ³£ÓÐׯÉÕ°ãµÄ¾çÍ´¸Ð£¬²¢°éÓÐÉÙº¹¡¢ÎÞº¹ºÍ²»É¢ÈȵÄÖ¢×´¡£Ëæ×Ų¡³Ì½øÕ¹£¬Ö¢×´»áÖð½¥¼ÓÖØ²¢³öÏÖÉö¡¢ÐÄµÈÆ÷¹Ù²¡±ä£¬ÖîÈçÑÏÖØµÄÉö¹¦ÄÜË¥½ßÉõÖÁÊÇÄò¶¾Ö¢£¬»òÄÔ×äÖС¢Ð£ÈûµÈÐÄÄÔѪ¹Ü²¢·¢Ö¢£¬ÈçµÃ²»µ½ÓÐЧÖÎÁƽ«ÑÏÖØÎ£¼°ÉúÃü¡£[3]

Ã¸Ìæ´úÖÎÁƱ»¹úÍâÖ¸ÄÏ/¹²Ê¶ÍƼöΪ·¨²¼Àײ¡µÄÒ»ÏßÁÆ·¨¡£2013Äê°æµÄÖйúFabry²¡ÕïÖÎר¼Ò¹²Ê¶ÖÐÒ²Ìá¼°£º¶à¸öËæ»ú¶ÔÕÕ¼°¿ª·ÅÀ©Õ¹ÁÙ´²ÊÔÑé½á¹û¾ùÏÔʾ£¬Ã¸Ìæ´úÖÎÁÆ·¨²¼Àײ¡¿É¼õÉÙ»¼Õßϸ°ûÄÚGL3µÄ³Á»ý£¬¼õÇỼÕßµÄÖ«¶ËÌÛÍ´¡¢Î¸³¦µÀÖ¢×´£¬¸ÄÉÆÐļ¡·Êºñ£¬Îȶ¨Éö¹¦ÄÜ£¬¸ÄÉÆ»¼ÕßµÄÉú»îÖÊÁ¿ºÍÔ¤ºó¡£[3]

ÉϺ£½»Í¨´óѧҽѧԺ¸½ÊôÈð½ðÒ½ÔºÉöÄÚ¿ÆÖ÷ÈÎҽʦ³Â骽ÌÊÚ±íʾ£º¡°·¨²¼Àײ¡µ¼ÖÂµÄÆ÷¹ÙËðÉ˼¸ºõÊDz»¿ÉÄæµÄ£¬ÈçµÃ²»µ½¼°Ê±ÓÐЧµÄÖÎÁÆ£¬»¼ÕßµÄÉö¡¢ÐĵÈÖØÒªÆ÷¹Ù»á²úÉúÑÏÖØµÄ¹¦ÄÜË𺦺Ͳ¡±ä£¬Î£¼°ÉúÃü¡£ÈðÆÕ¼Ñ®£¨°¢¼ÓÌÇø¦Á×¢ÉäÓÃŨÈÜÒº£©µÄÁÆÐ§ÒѾ­ÓÐ20ÄêµÄÕæÊµÊÀ½çÊý¾ÝÑéÖ¤£¬½«ÎªÖйú·¨²¼À×»¼Õß´øÀ´¸ü¶àµÄÖÎÁÆÑ¡Ôñ¡£¡±

¹ýÈ¥£¬ÓÉÓÚ·¨²¼Àײ¡ÖªÏþÂʵͣ¬ÇÒȱ·¦Õï¶Ï¼¼ÊõºÍתÕï;¾¶£¬»¼ÕßÈ·Õïʱ¼äÐèÒª³¤´ïÊýÊ®ÄêÖ®¾Ã[4]¡£Ä¿Ç°£¬¹úÄڴ󲿷ַ¨²¼À×»¼ÕßÈÔÔÚ½ÓÊܶÔÖ¢¸ÉÔ¤£¬Èçֹʹ¡¢Éö͸Îö¡¢°²×°ÐÄÔàÆð²«Æ÷µÈ£¬µ¼Ö´ó¶àÊý»¼ÕßÎÞ·¨¿ØÖƲ¡Ç飬ÑÏÖØÓ°Ï컼Õ߸öÈ˺ͼÒÍ¥Éú»îÖÊÁ¿£¬Òò¶øØ½´ýÍ»ÆÆÐÔÁÆ·¨ç£½âÉú´æÀ§¾Ö¡£2018Ä꣬·¨²¼Àײ¡Î»ÁÐÓɹú¼ÒÎÀ½¡Î¯µÈÎ岿ÃÅÁªºÏÖÆ¶¨µÄ¡¶µÚÒ»Åúº±¼û²¡Ä¿Â¼¡·[5]£¬¸ÃĿ¼ּÔÚ¼ÓËÙº±¼û²¡ÁÆ·¨ÉóÆÀºÍÉÏÊнø³Ì¡¢¸ÄÉÆ»¼ÕßÉú»îÖÊÁ¿¡£

ÎäÌïÖйú×ܲõ¥¹úºéÏÈÉú±íʾ£º¡°·Ç³£¸ÐлÏà¹ØÕþ¸®²¿ÃŵÄÓÅÏÈÉóÆÀºÍÉóÅú£¬ÈÃÈðÆÕ¼Ñ®£¨°¢¼ÓÌÇø¦Á×¢ÉäÓÃŨÈÜÒº£©¿ìËٻݼ°Öйú»¼Õߣ¬³ä·Öչʾ³öÕþ¸®ÔÚ¼ÓËÙÒýÈë¸ßÖÊÁ¿º±¼û²¡´´ÐÂÒ©Îï·½ÃæµÄ¾öÐĺÍÁ¦¶È¡£ÎäÌïʼÖÕ±ü³Ö¡®»¼ÕßΪÏÈ¡¯µÄÀíÄЯÊÖ¸÷·½¼ÓËÙÒýÈë¸ü¶àÈ«ÇòÊ×´´¡¢»¼Õß¼±ÐèµÄÒ©ÎÈÃÖйúº±¼û²¡»¼ÕßÄÜÓëÈ«ÇòÆäËûµØÇøµÄ»¼Õßͬ²½»ñµÃ×î¾ß´´ÐÂÐÔµÄÒ©Î¸Ä±äµ±Ç°»¼Õß¡®ÎÞÒ©¿ÉÖΡ¯µÄÀ§¾³¡£¡±

[1] Cardio-renal outcomes with long-term agalsidase alfa enzyme replacement therapy: a 10-year Fabry Outcome Survey (FOS) analysis. Ramaswami U, et al. Drug Des Devel Ther. 2019:13:3705-3715.

[2] ¹ú¼ÒÒ©Æ·¼à¶½¹ÜÀí¾ÖÒ©Æ·ÉóÆÀÖÐÐÄ£¬¹ØÓÚ·¢²¼µÚ¶þÅúÁÙ´²¼±Ðè¾³ÍâÐÂÒ©Ãûµ¥µÄ֪ͨ£¬http://www.cde.org.cn/news.do?method=viewInfoCommon&id=8ed064bd7e51fe68

[3] Öйú·¨²¼Àﲡ£¨Fabry²¡£©ÕïÖÎר¼Ò¹²Ê¶£¬ÖлªÒ½Ñ§ÔÓÖ¾2013Äê1ÔÂ22ÈÕµÚ93¾íµÚ4ÆÚ

[4] Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. A. Mehta, et al., European Journal of Clinical Investigation ; 2004-34: 236 242

[5] ÈËÃñ½¡¿µÍø£¬¹ú¼ÒÎÀÉú½¡¿µÎ¯Ô±»áµÈÎ岿ÃÅÁªºÏÖÆ¶¨¡¶µÚÒ»Åúº±¼û²¡Ä¿Â¼¡·£¬http://health.people.com.cn/n1/2018/0611/c14739-30050014.html


Ïà¹ØÈÈ´ÊËÑË÷£º
¹ØÓÚÎÒÃÇ ÁªÏµÎÒÃÇ ÈËÔ±²éѯ ÃâÔðÉùÃ÷ ÓÑÇéÁ´½Ó ¹óÖÝÍøLOGO ¹ã¸æ¿¯Àý ±¾Õ¾ÓòÃû °Ù¶ÈÐÂÎÅ